Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,016
datasets available to search
ShareScore release 0.9.0
Dataset results
5,016 results for “THERAPEUTICS”
Data from: Pharmacokinetics of morphine in encephalopathic neonates treated with therapeutic hypothermia
Objective: Morphine is a commonly used drug in encephalopathic neonates treated with therapeutic hypothermia after perinatal asphyxia. Pharmacokinetics and optimal dosing of morphine in this population are largely unknown. The objective of this study was to describe pharmacokinetics of morphine and its metabolites morphine-3-glucuronide and morphine-6-glucuronide in encephalopathic neonates treated with therapeutic hypothermia and to develop pharmacokinetics based dosing guidelines for this population. Study design: Term and near-term encephalopathic neonates treated with therapeutic hypothermia and receiving morphine were included in two multicenter cohort studies between 2008-2010 (SHIVER) and 2010-2014 (PharmaCool). Data were collected during hypothermia and rewarming, including blood samples for quantification of morphine and its metabolites. Parental informed consent was obtained for all participants. Results: 244 patients (GA mean (sd) 39.8 (1.6) weeks, BW mean (sd) 3,428 (613) g, male 61.5%) were included. Morphine clearance was reduced under hypothermia (33.5°C) by 6.89%/°C (95% CI 5.37%/°C – 8.41%/°C, p<0.001) and metabolite clearance by 4.91%/°C (95% CI 3.53%/°C – 6.22%/°C, p<0.001) compared to normothermia (36.5°C). Simulations showed that a loading dose of 50 μg/kg followed by continuous infusion of 5 μg/kg/h resulted in morphine plasma concentrations in the desired range (between 10 and 40 μg/L) during hypothermia. Conclusions: Clearance of morphine and its metabolites in neonates is affected by therapeutic hypothermia. The regimen suggested by the simulations will be sufficient in the majority of patients. However, due to the large interpatient variability a higher dose might be necessary in individual patients to achieve the desired effect.
Data from: Health Canada's use of accelerated review pathways and therapeutic innovation, 1995-2016: a cohort study
Objectives: This study examines the use of accelerated approval pathways by Health Canada over the period 1995 to 2016 inclusive and the relationship between the use of these pathways and the therapeutic gain offered by new products. Design: Cohort study. Data sources: Therapeutic Products Directorate, Biologics and Genetic Therapies Directorate, Notice of Compliance database, Notice of Compliance with conditions web site, Patented Medicine Prices Review Board, La revue Prescrire, World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system. Interventions: None. Primary and secondary outcomes: Percent of new drugs evaluated by Health Canada that went through an accelerated pathway between 1995 and 2016 inclusive. Kappa values comparing the review status to assessments of therapeutic value for individual drugs. Results: 438 (70.3%) drugs went through the standard pathway, 185 (29.7%) an accelerated pathway. Therapeutic evaluations were available for 509 drugs. Health Canada used an accelerated approval pathway for 159 of the 509 drugs whereas only 55 were judged to be therapeutically innovative. The Kappa value for the entire period for all 509 drugs was 0.276 (95% CI 0.194, 0.359) or fair. Conclusion: Health Canada's use of accelerated approvals was stable over the entire time period. Its ability to predict which drugs will offer a major therapeutic gain is relatively poor. The findings in this study should provoke a discussion about whether Health Canada should continue to use these pathways and if so how their use can be improved.
FSP1 is a predictive biomarker of osteosarcoma cells' susceptibility to ferroptotic cell death and a potential therapeutic target.
Open the record for dataset details and reuse information.
Unveiling Therapeutic Targets and Immunological Insights in Glioblastoma Through Analysis of Glioma-Associated Mesenchymal Stem Cells
<p>To analyze the binding affinities and interaction modes between the drug candidates and their targets, we employed the Autodock Vina software [21]. Molecular structures of the candidate drugs and targets of hub genes were retrieved from Pubchem (https://pubchem.ncbi.nlm.nih.gov/) and Protein Data Bank database (http://www.rcsb.org/), respectively. <span>In the analysis of docking, the files for all proteins and molecules were converted to PDBQT format. Water molecules were removed and polar hydrogen atoms were added. The grid box was positioned at the center to encompass the protein domain, allowing for unrestricted movement of molecules.</span></p>
JNK signaling provides a novel therapeutic target for Rett syndrome
<p>Raw data available at this link: https://zenodo.org/record/5608558#.YXrZnsZabJ8</p>
Figure 1 from: Yordanov Y (2019) Caffeic acid phenethyl ester (CAPE): pharmacodynamics and potential for therapeutic application. Pharmacia 66(3): 107-114. https://doi.org/https://doi.org/10.3897/pharmacia.66.e38573
Figure 1 Chemical structure of CAPE.
Images Dataset for the Work of Phase Separation-based Antiviral Decoy Particles as Basis for Programmable Broad-spectrum Therapeutics
<p>Images dataset for the work of Phase Separation-based Antiviral Decoy Particles as Basis for Programmable Broad-spectrum Therapeutics.</p> <p>Used for the code cited in the paper.</p>
Bulk RNA-seq count matrices from manuscript: "Therapeutic efficacy of intracerebral hematopoietic stem cell gene therapy in an Alzheimer's disease mouse model"
<p>Gene expression profile of microglia-like cells in the central nervous system (CNS) after transplantation of hematopoietic stem/progenitor cells (HSPC). </p> <p>Different cell subsets and delivery routes are tested to induce a robust and exclusive engraftment of HSPCs and their progeny in the CNS of mice transplant recipients.</p>
Dataset related to: "Are Extracorporeal Shock Waves Just a Therapeutic Tool?"
<p>We provide the raw data used for the following article:</p> <p>Gialanella B, Comini L, Bonometti GP, Vanoglio F, Bettinsoli A, Santoro R, Olivares A, Luisa A. <strong>Are Extracorporeal Shock Waves Just a Therapeutic Tool?</strong> Diagnostics 2024, 14, 2440. https://doi.org/10.3390/diagnostics14212440. </p> <p>Abstract: Background: Focused extracorporeal shock wave therapy (ESWT) has been successfully<br>used to treat musculoskeletal conditions, but ESWT stimulates nociceptors, causing pain deep in<br>the tissue during treatment. The occurrence of pain during ESWT is a side effect, but it can help<br>identify painful sites and assess minimum (MiTI) and maximum (MaTI) pain thresholds to ESWT<br>pressure stimuli. This topic has received limited attention in literature. Methods: This observational<br>study describes a specific approach to using ESWT to study pain in 71 patients. The approach<br>proposes moving the ESWT transducer head of the device over the entire joint surface, progressively<br>increasing the energy level until the patient experiences pain. Results: In the study, MiTI and<br>MaTI were 0.218 ± 0.090 and 0.416 ± 0.165 mJ/mm2 in the affected joint and 0.282 ± 0.128 and<br>0.501 ± 0.174 mJ/mm2 in the contralateral homologous healthy joint, being significantly lower in the<br>affected joint (MiTI: p < 0.001 and MaTI: p = 0.003, respectively). ESWT induced pain in 94.37% of<br>the sites with the highest subjective pain and in a greater number of sites (204) than digital pressure<br>(123) (p < 0.001). All sites with digital pressure pain also had ESWT pain. Conclusions: These results<br>suggest that the ESWT device may be useful in investigating pain in musculoskeletal conditions and<br>tailoring therapy.</p>
Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)
ClinicalTrials.gov study NCT01354613. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
ClinicalTrials.gov study NCT06764459. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Blood-Brain Barrier Penetration of Therapeutic Agents in Human
ClinicalTrials.gov study NCT04571996. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Diabetic Patients Needs in Therapeutic Education About Work. TE-DIW (Therapeutic Education of DIabetic Working People)
ClinicalTrials.gov study NCT03893266. IPD Sharing: NO. Countries: 1. Publications: 0.
Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus
ClinicalTrials.gov study NCT01375101. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy of a Dedicated Therapeutic Education Program in Patients at High Cardiovascular Risk
ClinicalTrials.gov study NCT01622400. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Microbiota: Its Role in Chronic Inflammation, IDB and Risk of Colorectal Cancer. Evaluation of a Predictive Prognostic Model With Therapeutic Implications
ClinicalTrials.gov study NCT07106463. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
ClinicalTrials.gov study NCT06959979. IPD Sharing: NO. Countries: 1. Publications: 0.
Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis
ClinicalTrials.gov study NCT02029586. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization
ClinicalTrials.gov study NCT00479895. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Circadian Modulation of Neurophysiological Responses to Therapeutic Massage Modalities
ClinicalTrials.gov study NCT07367607. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.